|
Application value of fecal SDC2 gene methylation test in early colorectal tumor diagnosis
LI Chuangkun, HUANG Yingfeng, ZOU Liaonan, LI Xiaoying, LUO Jie, NIU Feng, ZHAO Risheng, WANG Huaiming, WANG Hui, HUANG Rongkang
2020, 9 (1):
10-13.
doi: 10.3969/j.issn.2095-378X.2020.01.003
Objective To investigate the value of fecal SDC2 gene methylation test in early colorectal tumor diagnosis. Methods Medical records data of 134 enrolled patients were collected from six hospitals from January 2018 to December 2018. The sensitivity and specificity between fecal SDC2 gene methylation test and serum carcinoembryonic antigen (CEA) test for early colorectal tumor diagnosis were compared. Results Of the 134 enrolled cases, 86 cases were without colorectal tumors, 22 cases with colorectal adenoma, and 26 cases with colorectal cancer. Fecal SDC2 gene methylation was detected positive in 45 patients and negative in 89 patients. Serum CEA was detected positive in 16 patients and negative in 118 patients. In the 26 patients with colorectal cancer, the positive rate of SDC2 gene methylation (88.46%) was higher than that of serum CEA (27.59%), indicating that the sensitivity of SDC2 gene methylation test was higher than that of serum CEA test for patients with colorectal cancer (P<0.001). In the 22 patients with colorectal adenoma, the positive rate of SDC2 gene methylation was higher than that of serum CEA (22.73% vs. 4.54%, P=0.185). Conclusion Compared with serum CEA test, fecal SDC2 gene methylation test has a higher sensitivity in the diagnosis of colorectal tumor and precancerous lesions, and its role in the early diagnosis of colorectal tumor requires to be investigated in a larger sample size.
References |
Related Articles |
Metrics
|